Philips Beats on Orders and Margin, Reiterates 2026 Outlook as DOJ Settlement Takes Shape
PHG sits 17% above its 52-week low of $23.62 on elevated volume (2.2× avg).
Summary
Philips posted 8% comparable order intake growth and 3% comparable sales growth to EUR 4.4 billion in Q3, with adjusted EBITA margin up 70 basis points to 13.0% and expansion in all three segments. Income from operations was EUR 165 million and free cash flow reached EUR 384 million. The bigger item is legal: Respironics reached an agreement in principle with the US Department of Justice over the recall-related criminal and civil investigations, and Philips booked a EUR 288 million provision with payment expected in Q1 2027. Management reiterated the full-year 2026 outlook of 3%-4.5% comparable sales growth, a 13.5%-14.0% adjusted EBITA margin and EUR 1.5-1.7 billion free cash flow, which assumes the DOJ payment lands next quarter. Philips also issued EUR 650 million fixed rate notes due 2034, the healthcare industry's first EU Green Bond under the new European Green Bond Standard, 2.7 times oversubscribed. This follows the October 9 FDA safety alert on the Lumify ultrasound system, so the clean margin and order trends plus a path to closing out the recall overhang are the story here. The CEO and CFO host a call at 10:00 am CET today.
Updated with an SEC 6-K filing · What changed
Updates
· SEC 6-K — Philips issued EUR 650 million fixed rate notes due 2034, the healthcare industry's first EU Green Bond under the new European Green Bond Standard, 2.7 times oversubscribed.
At the time of this announcement, PHG was trading at $27.59 on NYSE in the Life Sciences sector, with a market capitalization of approximately $26.3B. The 52-week trading range was $23.62 to $33.44. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.